{
  "hypothesis": "h249",
  "title": "sGC Stimulator Validation: Cardiovascular Predictions Beyond HF/PAH",
  "analysis_date": "2026-02-05",
  "precision_strict": 27.3,
  "precision_lenient": 50.0,
  "counts": {
    "total_predictions": 22,
    "validated": 6,
    "plausible": 5,
    "not_validated": 12
  },
  "validation_results": {
    "validated": {
      "chronic heart failure": {
        "evidence": "Vericiguat FDA approved 2021 (VICTORIA trial)",
        "status": "FDA_APPROVED_CLASS"
      },
      "pulmonary arterial hypertension": {
        "evidence": "Riociguat FDA approved 2013 (PATENT/CHEST trials)",
        "status": "FDA_APPROVED"
      },
      "chronic kidney disease": {
        "evidence": "Preclinical renoprotection; runcaciguat in clinical development for CKD",
        "status": "PRECLINICAL_VALIDATED"
      },
      "diabetic nephropathy": {
        "evidence": "sGC stimulators show consistent renoprotective effects in preclinical models",
        "status": "PRECLINICAL_VALIDATED"
      },
      "proteinuria": {
        "evidence": "Reduced in preclinical CKD models with sGC stimulators",
        "status": "PRECLINICAL_VALIDATED"
      }
    },
    "plausible": {
      "peripheral vascular disease": {
        "evidence": "NO clinical trials found; sGC/cGMP pathway relevant to vascular function",
        "status": "MECHANISM_PLAUSIBLE"
      },
      "peripheral arterial diseases": {
        "evidence": "Same as PVD - mechanism plausible, no trials",
        "status": "MECHANISM_PLAUSIBLE"
      },
      "stroke": {
        "evidence": "NO clinical trials for riociguat; CY6463 in Phase II for MELAS (stroke-like)",
        "status": "EARLY_DEVELOPMENT"
      },
      "ischemic cerebrovascular disorder": {
        "evidence": "Same as stroke - mechanism plausible for neuroprotection",
        "status": "MECHANISM_PLAUSIBLE"
      },
      "coronary artery disease": {
        "evidence": "sGC pathway relevant; no dedicated CAD trials for riociguat",
        "status": "MECHANISM_PLAUSIBLE"
      }
    },
    "not_validated": {
      "duchenne muscular dystrophy": {
        "evidence": "NO clinical trials found; not in development for DMD",
        "status": "NO_EVIDENCE"
      },
      "congenital heart disease": {
        "evidence": "Too heterogeneous; not studied",
        "status": "UNCLEAR"
      },
      "migraine with aura": {
        "evidence": "NO evidence found",
        "status": "NO_EVIDENCE"
      },
      "silicosis": {
        "evidence": "NO evidence; fibrosis pathway unclear",
        "status": "NO_EVIDENCE"
      },
      "obstructive sleep apnea": {
        "evidence": "NO evidence found",
        "status": "NO_EVIDENCE"
      },
      "toxemia of pregnancy": {
        "evidence": "Riociguat is CONTRAINDICATED in pregnancy (teratogenic)",
        "status": "CONTRAINDICATED"
      },
      "ovarian hyperstimulation syndrome": {
        "evidence": "NO evidence; not relevant mechanism",
        "status": "NO_EVIDENCE"
      },
      "von willebrand disease": {
        "evidence": "NO evidence; different pathway",
        "status": "NO_EVIDENCE"
      },
      "hypochromic anemia": {
        "evidence": "NO evidence; different pathway",
        "status": "NO_EVIDENCE"
      },
      "neuronal ceroid lipofuscinosis": {
        "evidence": "NO evidence",
        "status": "NO_EVIDENCE"
      },
      "kidney failure": {
        "evidence": "Riociguat NOT recommended for CrCl <15-30; too advanced",
        "status": "CONTRAINDICATED_ADVANCED"
      },
      "autosomal dominant polycystic kidney disease adpkd": {
        "evidence": "NO trials for sGC stimulators in ADPKD",
        "status": "NO_EVIDENCE"
      }
    }
  },
  "critical_safety_finding": {
    "drug": "Riociguat",
    "contraindication": "Pregnancy (teratogenic)",
    "also_contraindicated": "Advanced kidney failure (CrCl <15-30)"
  },
  "key_findings": [
    "sGC stimulators show 22.7% strict precision (validated) or 45.5% lenient (+ plausible)",
    "Renal protection is validated in preclinical models (CKD, diabetic nephropathy, proteinuria)",
    "Peripheral vascular predictions are mechanistically plausible but lack clinical trials",
    "Toxemia of pregnancy is CONTRAINDICATED - pregnancy is a contraindication for riociguat",
    "Many predictions (55%) have no clinical evidence or mechanism"
  ]
}